Small-cap Health Care company Acelyrin has moved -32.4% so far today on a volume of 6,234,450, compared to its average of 1,299,606. In contrast, the S&P 500 index moved 0.0%.
Acelyrin trades -82.18% away from its average analyst target price of $33.0 per share. The 4 analysts following the stock have set target prices ranging from $15.0 to $68.0, and on average have given Acelyrin a rating of buy.
Anyone interested in buying SLRN should be aware of the facts below:
-
Based on its trailing earnings per share of -5.06, Acelyrin has a trailing 12 month Price to Earnings (P/E) ratio of -1.2 while the S&P 500 average is None
-
SLRN has a forward P/E ratio of -1.3 based on its forward 12 month price to earnings (EPS) of $-4.54 per share
-
Its Price to Book (P/B) ratio is 0.78 compared to its sector average of None
-
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines.
-
Based in Agoura Hills, the company has 108 full time employees and a market cap of $571.77 Million.